Last reviewed 2026-05-24 · How we verify

VB-111 + Paclitaxel

Vascular Biogenics Ltd. operating as VBL Therapeutics · Phase 3 active Small molecule Under review

VB-111 + Paclitaxel is a VEGF aptamer and microtubule inhibitor Small molecule drug developed by Vascular Biogenics Ltd. operating as VBL Therapeutics. It is currently in Phase 3 development for Recurrent Glioblastoma. Also known as: Ofranergene Obadenovec.

VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.

VB-111, a small molecule inhibitor of Toll-like receptor 2, is being studied in combination with Paclitaxel for the treatment of recurrent platinum-resistant ovarian cancer. The study, NCT03398655, is a randomized, double-blind, controlled trial comparing VB-111 + Paclitaxel to Placebo + Paclitaxel and Paclitaxel alone.

Likelihood of approval

64.3% vs 58.3% industry baseline

If approved by FDA: likely 2028–2030

Steps remaining: NDA/BLA submission

Confidence: High

Why this estimate

Baseline phase 3 → approval rate +58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
Oncology Phase 3 boost +3.0pp
Oncology Phase 3 trials have higher approval rates (~61%) than the cross-industry average due to clearer endpoints and FDA oncology pathway.
Big-pharma sponsor +3.0pp
Vascular Biogenics Ltd. operating as VBL Therapeutics is a top-20 pharma sponsor — historical approval rates run ~3pp above average due to scale, regulatory experience, and trial-design quality.

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2028–2030	—
EMA	EU	2029–2031	+0.7 yr
MHRA	GB	2029–2031	+0.7 yr
Health Canada	CA	2029–2032	+0.9 yr
TGA	AU	2029–2032	+1.2 yr
PMDA	JP	2029–2032	+1.5 yr
NMPA	CN	2030–2033	+2.3 yr
MFDS	KR	2029–2032	+1.4 yr
CDSCO	IN	2029–2033	+1.8 yr
ANVISA	BR	2030–2033	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	VB-111 + Paclitaxel
Also known as	Ofranergene Obadenovec
Sponsor	Vascular Biogenics Ltd. operating as VBL Therapeutics
Drug class	VEGF aptamer and microtubule inhibitor
Target	VEGF
Modality	Small molecule
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

The combination of VB-111 and Paclitaxel targets both the tumor vasculature and the rapidly dividing cancer cells, leading to a synergistic anti-tumor effect. VB-111 binds to VEGF, preventing it from interacting with its receptor and thereby inhibiting angiogenesis, while Paclitaxel stabilizes microtubules, preventing cell division and leading to cell death.

Approved indications

Recurrent Glioblastoma

Common side effects

Fatigue
Nausea
Vomiting

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

VB-111 + Paclitaxel CI brief — competitive landscape report
VB-111 + Paclitaxel updates RSS · CI watch RSS
Vascular Biogenics Ltd. operating as VBL Therapeutics portfolio CI

Frequently asked questions about VB-111 + Paclitaxel

What is VB-111 + Paclitaxel?

VB-111 + Paclitaxel is a VEGF aptamer and microtubule inhibitor drug developed by Vascular Biogenics Ltd. operating as VBL Therapeutics, indicated for Recurrent Glioblastoma.

How does VB-111 + Paclitaxel work?

VB-111 is a targeted anti-vascular endothelial growth factor (VEGF) aptamer that inhibits tumor growth by blocking VEGF, while Paclitaxel is a microtubule inhibitor that disrupts cell division.

What is VB-111 + Paclitaxel used for?

VB-111 + Paclitaxel is indicated for Recurrent Glioblastoma.

Who makes VB-111 + Paclitaxel?

VB-111 + Paclitaxel is developed by Vascular Biogenics Ltd. operating as VBL Therapeutics (see full Vascular Biogenics Ltd. operating as VBL Therapeutics pipeline at /company/vascular-biogenics-ltd-operating-as-vbl-therapeutics).

Is VB-111 + Paclitaxel also known as anything else?

VB-111 + Paclitaxel is also known as Ofranergene Obadenovec.

What drug class is VB-111 + Paclitaxel in?

VB-111 + Paclitaxel belongs to the VEGF aptamer and microtubule inhibitor class. See all VEGF aptamer and microtubule inhibitor drugs at /class/vegf-aptamer-and-microtubule-inhibitor.

What development phase is VB-111 + Paclitaxel in?

VB-111 + Paclitaxel is in Phase 3.

What are the side effects of VB-111 + Paclitaxel?

Common side effects of VB-111 + Paclitaxel include Fatigue, Nausea, Vomiting.

What does VB-111 + Paclitaxel target?

VB-111 + Paclitaxel targets VEGF and is a VEGF aptamer and microtubule inhibitor.

Drug class: All VEGF aptamer and microtubule inhibitor drugs
Target: All drugs targeting VEGF
Manufacturer: Vascular Biogenics Ltd. operating as VBL Therapeutics — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Recurrent Glioblastoma
Also known as: Ofranergene Obadenovec

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing